# persevERA (NCT04546009)

> A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

No report yet. It can be ordered.

- Drugs tested: giredestrant plus palbociclib

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04546009
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Hoffmann-La Roche
- Conditions: Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
- Interventions: Giredestrant; Giredestrant-matched Placebo; Letrozole; Letrozole-matched Placebo; Palbociclib; LHRH Agonist
- Enrollment: 992
- Primary outcome: Progression-Free Survival (PFS), as Determined by the Investigator According to RECIST v1.1

## Indexed commentary on persevERA so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 38 YouTube videos
- 35 posts on X
- 34 podcast episodes
- 1 video on X

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=persevera-nct04546009

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04546009", "email": "<work email>"}; the inbox owner confirms by the emailed link.